Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Advisory Panel Backs Takeda Ulcerative Colitis Drug
December 11, 2013
- Santen Sets Up Local Subsidiary in Singapore
December 11, 2013
- Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
- Ono to Launch PI Study on Peptide-Cocktail Vaccine for HCC
December 11, 2013
- GSK Launches Asthma Treatment Relvar
December 11, 2013
- Drug Makers Invest in Developing AD Treatments
December 10, 2013
- Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
- Santen Files MAA for Ciclosporin for Dry Eye Disease in Europe
December 10, 2013
- Veep Kawasaki to Be Elevated to President of inVentiv Health Japan
December 9, 2013
- Survey Finds 1.7-Fold Increase in Patients Prescribed DPP-4 Inhibitors Over 2-Year Period: MDV
December 9, 2013
- ViiV Healthcare Files NDA for Anti-HIV Treatment Dolutegravir in Japan
December 9, 2013
- “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End
December 9, 2013
- Fujifilm to Initiate Joint PII Study of AD Treatment with ADCS
December 9, 2013
- Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use
December 6, 2013
- Kyowa Kirin Shutters Yokkaichi Plant
December 6, 2013
- M3 to Make Mediscience Planning Its Wholly Owned Subsidiary
December 6, 2013
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
- Takeda to Market Teva’s Multiple Sclerosis Treatment in Japan
December 5, 2013
- Sawai President Requests Cautious Discussions on Generic Prices, Shows Confidence in Surviving
December 5, 2013
- “Big Gap” Remains to Reach 5-Year Profit Target: Astellas Pres.
December 5, 2013
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…